In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Alkermes plc

Novartis Advances Novel Kidney Disease Therapy Iptacopan

Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.

Clinical Trials Commercial

Stockwatch: Will Biogen Keep Digging After Tough Quarter?

Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.

Sales & Earnings Coronavirus COVID-19

Coronavirus Update: AstraZeneca’s Vaccine Trials Cleared To Restart In the US, J&J Prepares To Restart Its Vaccine Study

Two potential COVID-19 vaccine trials from AstraZeneca and Johnson & Johnson are set to resume in the US following temporary pauses due to safety concerns. Data from both could come later this year.

Coronavirus COVID-19 Clinical Trials

Coronavirus Vaccines As A Public Good: How Reasonable Is Reasonable?

During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Rodin Therapeutics, Inc.
UsernamePublicRestriction

Register